- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Minnesota Legislator Discusses Bill to Broaden Biosimilar Coverage
State Representative Jennifer Schultz (D, Duluth) explains how her bill requiring payers to cover all approved biosimilars and reference products would save money and improve access.
Recently, legislators in Minnesota introduced a bill that could force health plans and pharmacy benefit managers (PBMs) to provide equal coverage for biosimilars and reference products, removing the ability for plans to prefer higher-cost originators or limited numbers of biosimilars. The bipartisan bill was designed by Representative Jennifer Schultz (D, Duluth) and Senator Carla Nelson (R, Rochester) and was drafted in consultation with research scientists at Essentia Health and the Mayo Clinic.
We spoke with Schultz, who has a PhD in health economics, to discuss why a bill like this is needed in Minnesota and how it can help foster competition in the biologics market.
To learn more about the bill, click here.
To read the bill’s official text, click here.
To learn more about payer formulary preferences, click here.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
